Drug intelligence / Profile preview

FKC516

Development stage: Preclinical
Lead developer: Fosun Kairos
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

FKC516 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy being developed by Fosun Kairos, the innovation arm of Fosun Kite Biotechnology. It is designed for the treatment of large B-cell lymphoma (LBCL). As an autologous cell therapy, FKC516 involves the ex vivo genetic modification of a patient's own T cells to express a CAR that targets specific antigens on the surface of lymphoma cells. Once re-infused into the patient, these engineered cells are intended to recognize and induce the lysis of malignant B cells. The program is currently in the preclinical and IND-enabling stages of development.

Beyond the preview

Go deeper on FKC516.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FKC516.

Explore the full profile